This protocol is judged by an institutional overview board, an unbiased team that reviews any clinical trials involving individuals. If a study requires a Plan I drug, when the board approves the protocol as ethical, the researchers really need to make an application for an investigational new drug (IND) variety in the FDA.In MAPS’s case, the med